K. Wisinski

G. Wilding, J. Kolesar, J. Eickhoff, 2015, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

Amy M. Sitapati, W. Gradishar, R. Aft, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Breast Cancer, Version 3.2022

Amy M. Sitapati, W. Gradishar, R. Aft, 2022 .

A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer

G. Wilding, J. Kolesar, K. Wisinski, 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021

So, B. Karlan, S. Friedman, 2020 .

Research resource: global identification of estrogen receptor β target genes in triple negative breast cancer cells.

S. Keleş, Wei Xu, K. Wisinski, 2013, Molecular endocrinology.

Constitutively decreased TGFBR1 allelic expression is a common finding in colorectal cancer and is associated with three TGFBR1 SNPs

N. Yi, D. Stram, B. Pasche, 2010, Journal of experimental & clinical cancer research : CR.

Reconstructing tumor trajectories during therapy through integration of multiple measurement modalities

Jason I. Griffiths, I. Makhoul, A. Bild, 2021, bioRxiv.

Open Access Research

N. Yi, D. Stram, B. Pasche, 2022 .

Researchdecreased TGFBR1 allelic expression is a common finding in colorectal cancer and is associated with three TGFBR1 SNPs

N. Yi, D. Stram, B. Pasche, 2010 .

Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.

M. Burkard, KyungMann Kim, A. Tevaarwerk, 2014, Clinical Breast Cancer.

Abstract P3-12-10: Feasibility of four cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: A Wisconsin oncology network study

M. Burkard, KyungMann Kim, A. Tevaarwerk, 2013 .

Identification of Estrogen Receptor Dimer Selective Ligands Reveals Growth-Inhibitory Effects on Cells That Co-Express ERα and ERβ

S. Keleş, E. Powell, W. Xu, 2012, PloS one.

Predictors of Willingness to Participate in Window-of-Opportunity Breast Trials

KyungMann Kim, J. McElroy, K. Wisinski, 2013, Clinical Medicine & Research.

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

B. Karlan, S. Friedman, K. Offit, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Microsoft Word-Fakhraldeen_JBC_R4.docx

A. Roopra, K. Wisinski, C. Alexander, 2015 .

A phase II trial of neoadjuvant MK2206, an AKT inhibitor, with anastrozole in clinical stage 2 or 3 PIK3CA mutant ER positive and HER2 negative breast cancer Estrogen receptor positive breast cancer, neoadjuvant endocrine therapy,

Erica K. Barnell, E. Mardis, O. Griffith, 2017 .

Concurrent Radiation and Modern Systemic Therapies for Breast Cancer: An Ever-Expanding Frontier.

K. Wisinski, J. Witt, B. Anderson, 2021, Clinical breast cancer.

Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.

Carlos L. Arteaga, R. Gray, K. Flaherty, 2022, JCO precision oncology.

HER2-positive/ER-low breast carcinoma shows a response to neoadjuvant chemotherapy similar to that of HER2-positive/ER-negative breast carcinoma.

K. Wisinski, Qiqi Yu, P. Weisman, 2022, Pathology, research and practice.

In the interest of full disclosure.

M. Burkard, A. Tevaarwerk, K. Wisinski, 2010, The Lancet Oncology.

Aromatase inhibitors and calcium absorption in early stage breast cancer

M. Burkard, M. Shafer, A. Tevaarwerk, 2012, Breast Cancer Research and Treatment.

Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer

N. Agarwal, J. Machiels, K. Wisinski, 2016, The oncologist.

Results from a prospective longitudinal survey of employment and work outcomes in newly diagnosed cancer patients during and after curative‐intent chemotherapy: A Wisconsin Oncology Network study

D. Wiegmann, K. Buhr, A. Onitilo, 2020, Cancer.

Tumor Cell-Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression.

Robert Langer, Michael J Cima, Douglas A Lauffenburger, 2016, Cancer discovery.

CARM1 Methylates Chromatin Remodeling Factor BAF155 to Enhance Tumor Progression and Metastasis.

P. Ahlquist, W. Cai, Menggang Yu, 2016, Cancer cell.

A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

S. Barry, G. Shapiro, C. Higano, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.

Amy M. Sitapati, W. Gradishar, R. Aft, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer

M. Burkard, J. Kolesar, KyungMann Kim, 2017, Investigational New Drugs.

BAF155 methylation drives metastasis by hijacking super-enhancers and subverting anti-tumor immunity

Jennifer L. Schehr, I. Ong, J. Lang, 2021, Nucleic acids research.

Stromal Characteristics and Impact on New Therapies for Metastatic Triple-Negative Breast Cancer

K. Wisinski, S. Ponik, Johanna E Poterala, 2022, Cancers.

Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer

R. Salgia, D. Wheeler, K. Wisinski, 2014, Molecular Cancer Therapeutics.

Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer

M. Burkard, J. Kolesar, J. Eickhoff, 2016, Clinical Cancer Research.

Title: Phase 1 study of an AKT-inhibitor (MK-2206) combined with lapatinib in adult solid tumors followed by dose-expansion in advanced HER2+ breast cancer Running title: Phase 1 of MK-2206 and lapatinib in combination Authors: 1)

M. Burkard, J. Kolesar, J. Eickhoff, 2016 .

Management of patients with HER2‐positive metastatic breast cancer: Is there an optimal sequence of HER2‐directed approaches?

K. Wisinski, A. Zelnak, 2015, Cancer.

Two Isoforms of the RNA Binding Protein, Coding Region Determinant-binding Protein (CRD-BP/IGF2BP1), Are Expressed in Breast Epithelium and Support Clonogenic Growth of Breast Tumor Cells*

Avtar Roopra, Wei Huang, Caroline M Alexander, 2015, The Journal of Biological Chemistry.

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.

S. Friedman, K. Offit, S. Buys, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as Prognostic Markers for Invasive Breast Carcinoma Patients.

Menggang Yu, Kevin W Eliceiri, Yanyao Yi, 2018, The American journal of pathology.

NCCN Guidelines® Insights: Breast Cancer, Version 4.2021.

Amy M. Sitapati, W. Gradishar, R. Aft, 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel

M. Burkard, J. Fitzgerald, Lauren M. Zasadil, 2021, Science Translational Medicine.

Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4/6 therapy

Jeffrey T. Chang, Jason I. Griffiths, I. Makhoul, 2021, Nature Cancer.

Inoperable pancreatic cancer: standard of care.

A. Benson, W. Small, K. Wisinski, 2007, Oncology.

A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782)

K. Wisinski, R. O'Regan, J. Malhotra, 2022, Cancer medicine.

BRCA Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations.

K. Maturen, K. Wisinski, L. Wilke, 2019, Radiology.

The Role of Molecular Markers in Predicting Response to Therapy in Patients with Colorectal Cancer

A. Benson, M. Mulcahy, K. Wisinski, 2012, Molecular Diagnosis & Therapy.

Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model

D. Beebe, K. Wisinski, M. Patankar, 2018, Oncoimmunology.

Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS–STING Signaling in Triple-Negative Breast Cancer

D. Beebe, M. Burkard, B. Weaver, 2021, Molecular Cancer Therapeutics.

Identification of Selective Lead Compounds for Treatment of High-Ploidy Breast Cancer

M. Burkard, Lauren M. Zasadil, B. Weaver, 2015, Molecular Cancer Therapeutics.

Letrozole + ribociclib versus letrozole + placebo as neoadjuvant therapy for ER+ breast cancer (FELINE trial).

I. Makhoul, A. Bardia, K. Wisinski, 2020 .

Endocrine Therapy for Breast Cancer

A. Tevaarwerk, K. Wisinski, R. O'Regan, 2018 .

Circulating Tumor Cells in Metastatic Breast Cancer: A Prognostic and Predictive Marker.

D. Beebe, K. Wisinski, S. F. Moussavi-Harami, 2014, Journal of patient-centered research and reviews.

Role of the androgen receptor in triple-negative breast cancer.

K. Wisinski, R. O'Regan, M. Rampurwala, 2016, Clinical advances in hematology & oncology : H&O.

Prognostic significance of full-length estrogen receptor beta expression in stage I-III triple negative breast cancer.

A. Onitilo, J. Engel, KyungMann Kim, 2015, American journal of translational research.

Original Article Prognostic significance of full-length estrogen receptor beta expression in stage I-III triple negative breast cancer

A. Onitilo, J. Engel, KyungMann Kim, 2015 .

Leveraging Antiprogestins in the Treatment of Metastatic Breast Cancer.

H. Rui, D. Yee, K. Wisinski, 2021, Endocrinology.

Antiestrogen Therapy Increases Plasticity and Cancer Stemness of Prolactin-Induced ERα+ Mammary Carcinomas.

A. Friedl, K. Wisinski, K. O'Leary, 2018, Cancer research.

Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk.

C. Mantzoros, K. Offit, B. Pasche, 2008, JAMA.

Treatment differences between urban and rural women with hormone receptor-positive early-stage breast cancer based on 21-gene assay recurrence score result.

A. Onitilo, J. Engel, KyungMann Kim, 2015, The Journal of community and supportive oncology.

Screening Magnetic Resonance Imaging Recommendations and Outcomes in Patients at High Risk for Breast Cancer

W. DeMartini, A. Tevaarwerk, K. Wisinski, 2015, The breast journal.

Organotypic microfluidic breast cancer model reveals starvation-induced spatial-temporal metabolic adaptations

Tiffany M. Heaster, Sean P. Palecek, D. Beebe, 2018, EBioMedicine.

A Survey of Baseline Tobacco Cessation Clinical Practices and Receptivity to Academic Detailing.

M. Fiore, K. Wisinski, R. Adsit, 2016, WMJ : official publication of the State Medical Society of Wisconsin.

Genomic Testing in the Management of Early-Stage Breast Cancer.

K. Wisinski, Sima Ehsani, 2017, Journal of clinical outcomes management : JCOM.

Genomic Testing in Women with Early-Stage Hormone Receptor – Positive , HER 2-Negative Breast Cancer

K. Wisinski, Sima Ehsani, 2017 .

Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study.

M. Burkard, KyungMann Kim, Wei Xu, 2016, Clinical breast cancer.

Identification of exosome protein biomarkers in patients with advanced hormone receptor-positive breast cancer treated with palbociclib and tamoxifen.

Menggang Yu, G. Mohapatra, D. Toppmeyer, 2022, Journal of Clinical Oncology.

Advances in the Treatment of Early-Stage HER2-Positive Breast Cancer.

K. Wisinski, M. Sharifi, 2020, Clinical advances in hematology & oncology : H&O.

Effects of culture method on response to EGFR therapy in head and neck squamous cell carcinoma cells

D. Beebe, P. Lambert, K. Wisinski, 2019, Scientific Reports.

Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2

Carlos L. Arteaga, R. Gray, K. Flaherty, 2023, JCO precision oncology.

Development and Evaluation of a Survey to Assess Survivor Knowledge Change After Survivorship Care Plans: WiSDOM-B (Wisconsin Survey of cancer DiagnOsis and Management in Breast cancer)

D. Wiegmann, K. Buhr, M. Sesto, 2014, Journal of Cancer Education.

AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer an

S. Barry, G. Shapiro, J. Bono, 2016 .

A phase I study of the oral platinum agent satraplatin (S) in with capecitabine (C) in patients (pts) with advanced solid malignancies

W. Gradishar, A. Benson, M. Mulcahy, 2008 .

A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors

C. Kyriakopoulos, J. Kolesar, J. Eickhoff, 2017, Investigational New Drugs.

Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer.

M. Burkard, J. Kolesar, KyungMann Kim, 2014 .

Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: MAINTAIN Trial

Prabhjot S. Mundi, K. Wisinski, E. Stringer-Reasor, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Supplemental Information CARM 1 Methylates Chromatin Remodeling Factor BAF 155 to Enhance Tumor Progression and Metastasis

P. Ahlquist, W. Cai, Menggang Yu, 2013 .

Panobinostat, a novel histone deacetylase inhibitor, in advanced medullary and iodine-refractory differentiated thyroid cancer: A Wisconsin Oncology Network trial.

Herb Chen, K. Wisinski, G. Leverson, 2013 .

NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.

W. Gradishar, R. Aft, M. Dwyer, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Tumor-on-a-chip: a microfluidic model to study cell response to environmental gradients.

D. Beebe, K. Wisinski, M. Skala, 2019, Lab on a chip.

Abstract CT139: NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations

R. Gray, K. Flaherty, L. Harris, 2019, Clinical Trials.

A phase I study of veliparib (Vel) in combination with oxaliplatin (Ox) and capecitabine (Cap) in advanced solid tumors.

J. Eickhoff, A. Tevaarwerk, K. Wisinski, 2018 .

Is the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years?

K. Wisinski, R. O'Regan, M. Sharifi, 2023, Clinical breast cancer.

Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center

G. Wilding, J. Kolesar, K. Wisinski, 2018, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020

S. Friedman, K. Offit, S. Buys, 2020, Journal of the National Comprehensive Cancer Network.

Cancer Biology and Signal Transduction Nuclear Epidermal Growth Factor Receptor Is a Functional Molecular Target in Triple-Negative Breast Cancer

R. Salgia, D. Wheeler, K. Wisinski, 2014 .

Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity

M. Burkard, A. Onitilo, J. Engel, 2011, Breast Cancer Research and Treatment.

BRCA Mutation Carriers: Breast and Ovarian Cancer Screening Guidelines and Imaging Considerations.

K. Maturen, K. Wisinski, L. Wilke, 2019, Radiology.

Tumor Cell-Driven Extracellular Matrix Remodeling Drives Haptotaxis during Metastatic Progression.

D. Lauffenburger, M. Cima, R. Langer, 2016, Cancer discovery.

Abstract OT1-02-01: Phase I trial of bicalutamide and ribociclib in androgen receptor-positive triple negative breast cancer

M. Burkard, K. Wisinski, R. O'Regan, 2019, Ongoing Clinical Trials.